- Poster presentation
- Open Access
PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
© Mestrallet et al.; licensee BioMed Central Ltd. 2013
- Published: 5 December 2013
- Retrospective Study
- Conventional Treatment
R ituximab is an anti-CD20 monoclonal antibody that has proven to be effective in the treatment of ANCA-associated vasculitis (AAV) in adults. Standard treatments rely on corticosteroids and cyclophosphamide. Only isolated case reports of pediatric AAV treated by rituximab have been reported so far.
Our objective was to collect clinical data and outcomes of children with AAV treated with rituximab in a multicenter retrospective study.
We conducted a retrospective study within the French paediatric rheumatology society (SOFREMIP) in 2011-2012.
We identified 6 children with AAV treated with rituximab (microscopic polyangeitis, n = 2, granulomatosis with polyangeitis, n = 2, unspecified vasculitis, n = 2). The age at onset ranged from 4 to 16 yrs. Treatment with rituximab consisted in 4 infusions of 375 mg/m2; one patient received only 3 infusions. Mean duration of follow-up was 2.65 yrs. All patients achieved clinical remission after 12 months. One patient presented several relapses associated with B cell increase and was dependent on rituximab infusions. No severe adverse event had been reported.
From this multicenter retrospective series, short-term safety and efficicacy of rituximab in pediatric AAV is promising so that B cell depleting agents may represent an alternative to conventional treatment with cyclophosphamide but larger prospective studies are mandatory.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.